8-K: Tvardi Therapeutics Unveils Promising Clinical Data for STAT3 Inhibitors in IPF and HCC, Files IND for Next-Gen TTI-109

Tvardi Therapeutics, Inc. has updated its corporate presentation, showcasing encouraging preliminary clinical data for its lead drug candidate TTI-101 in Idiopathic Pulmonary Fibrosis and Hepatocellular Carcinoma, alongside the Investigational New Drug (IND) filing for its next-generation STAT3 inhibitor, TTI-109.

Summary

• Tvardi Therapeutics, Inc. (TVRD) filed an 8-K to announce an updated corporate presentation, which is now available on its website for investors and analysts.
• The presentation highlights the company's strategic focus on targeting STAT3, a central mediator in fibrosis-driven diseases, with its lead product candidate, TTI-101.
• For Idiopathic Pulmonary Fibrosis (IPF), TTI-101 is currently in a Phase 2 REVERTIPF study, which is a double-blind, randomized, placebo-controlled trial over 12 weeks with enrollment completed (N=75).
• Preliminary blinded data from the REVERTIPF study indicates encouraging trends in lung function, with over 50% of subjects showing Forced Vital Capacity (FVC) values near or above baseline.
• Unblinded data from the IPF Phase 2 trial is anticipated in the fourth quarter of 2025.
• In Hepatocellular Carcinoma (HCC), TTI-101 demonstrated durable partial responses in Phase 1 monotherapy, achieving objective response rates that exceed the current standard of care for second-line HCC (which is typically less than 5%).
• An ongoing Phase 1b/2 REVERTLiver Cancer study for HCC is underway, with topline data expected in the first half of 2026, evaluating TTI-101 as monotherapy and in combination with pembrolizumab or atezolizumab/bevacizumab.
• The company announced the Investigational New Drug (IND) filing for TTI-109 in June 2025, which is described as a bioequivalent prodrug of TTI-101 with improved drug delivery and enhanced patent protection.
• The IPF market represents a significant unmet need, with an estimated prevalence of 150,000 and incidence of 50,000 in the US, and existing FDA-approved drugs (Ofev, Esbriet) only slowing disease progression.
• HCC is a major global health concern, ranking as the third leading cause of cancer deaths worldwide, with over 42,000 new cases and approximately 32,000 deaths annually in the US.

Sentiment

Score: 8

Explanation: The document presents highly encouraging preliminary clinical data for TTI-101 in two significant disease areas (IPF and HCC), with results that appear to outperform current standards of care or competitor trials. The IND filing for a next-generation compound (TTI-109) adds to the positive outlook. While data is preliminary and subject to change, the overall tone and reported outcomes are very positive, indicating strong progress and potential for the company's pipeline.

Positives

• TTI-101 demonstrated reversal of fibrosis and restoration of lung function in preclinical Idiopathic Pulmonary Fibrosis (IPF) models.
• Preliminary blinded data from the Phase 2 REVERTIPF study suggests encouraging trends in lung function, with over 50% of subjects showing FVC values near or above baseline, which is clinically significant.
• TTI-101 outperformed approved antifibrotics (nintedanib and pirfenidone) in repressing IPF-induced genes in ex vivo human lung slices.
• In Phase 1 Hepatocellular Carcinoma (HCC) monotherapy, TTI-101 led to durable partial responses, with one patient achieving a 66% reduction in sum of targets and sustained response for 14 months.
• TTI-101 was well-tolerated in clinical trials with no dose-limiting toxicities observed.
• The drug demonstrated target engagement by reducing pY-STAT3 levels in humans (55% overall, 79% in stable disease patients).
• The objective response rate (ORR) observed in Phase 1 HCC monotherapy (35% for HCC patients) significantly exceeds the current expected ORR for second-line HCC therapies (less than 5%).
• Preclinical and clinical data support a strong rationale for TTI-101 in combination with Immune Checkpoint Inhibition (ICI) therapy, showing potential to overcome ICI resistance.
• The Investigational New Drug (IND) for TTI-109, a next-generation STAT3 inhibitor with improved drug delivery and enhanced patent protection, was filed in June 2025.
• The company is led by a seasoned management team with deep research and development and operational expertise.

Negatives

• The clinical data presented for both IPF and HCC are preliminary, blinded, or interim, and thus have not been subjected to the standard quality control measures typically associated with final clinical trial results.
• Cross-study comparisons presented are inherently limited and may suggest misleading similarities and differences, and the values shown are directional and may not be directly comparable.
• The REVERTLiver Cancer Cohort C (TTI-101 + Atezo/Bev) showed an 8% ORR, which is lower than the 27% ORR reported for IMBrave150 (atezo/bev arm), although Tvardi notes their cohort has no HBV-associated HCC patients, which may impact comparability.
• The natural course of IPF is a decline in FVC, indicating the inherent challenge of demonstrating improvement or even stability in lung function for patients.

Risks

• Forward-looking statements contained in the presentation involve substantial risks and uncertainties, and actual results may differ materially from the plans, intentions, or expectations disclosed.
• There is no guarantee that the company will achieve the expected benefits, activity, effectiveness, and safety of its product candidates.
• Uncertainties exist regarding the design and results of research and development programs, preclinical studies, and clinical trials, including the timing and availability of data.
• The preclinical, clinical, and regulatory development plans for product candidates, including the timing or likelihood of regulatory filings and approvals, are subject to inherent risks.
• The potential market size and size of the potential patient populations for product candidates and any future product candidates may not materialize as projected.
• The company's ability to maintain existing and establish new strategic collaborations, licensing, or other arrangements is uncertain.
• The scope of protection the company is able to establish and maintain for intellectual property rights covering its product candidates is not guaranteed.
• Estimates and statistical data relating to market size and growth, as well as projections of future performance, are necessarily subject to a high degree of uncertainty and risk.
• Specific business risks are described in detail in the company's Securities and Exchange Commission filings, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.

Future Outlook

Tvardi Therapeutics anticipates releasing unblinded data from its Phase 2 REVERTIPF trial for Idiopathic Pulmonary Fibrosis in the fourth quarter of 2025. Topline data from the Phase 1b/2 REVERTLiver Cancer trial for Hepatocellular Carcinoma is expected in the first half of 2026. The company also plans to commence clinical trials for TTI-109 in fibrosis and/or oncology pending IND submission and FDA feedback.

Management Comments

• "We may use the corporate presentation from time to time in conversations with analysts, investors and others."
• The company possesses "deep expertise in STAT3 biology."
• TTI-101 has the "potential to serve as a disease-modifying therapy in IPF."
• The company is "well-positioned to differentiate therapeutic impact in HCC."
• The company expects "multiple near-term data catalysts."

Industry Context

Tvardi Therapeutics is positioning its STAT3 inhibitors, TTI-101 and TTI-109, to address significant unmet medical needs in Idiopathic Pulmonary Fibrosis (IPF) and Hepatocellular Carcinoma (HCC). In IPF, current FDA-approved therapies like Ofev and Esbriet primarily slow disease progression, leaving a substantial market for a disease-modifying treatment that can reverse fibrosis and restore lung function. Tvardi's approach aims to fill this gap. In HCC, a leading cause of cancer deaths, Tvardi seeks to improve upon existing first and second-line therapies, which often have limited response rates, by targeting STAT3 to overcome tumorigenesis and immune suppression, including resistance to immune checkpoint inhibitors. This strategy aligns with the industry's move towards more targeted and combination therapies for complex diseases.

Comparison to Industry Standards

• In IPF, TTI-101 demonstrated superior repression of IPF-induced genes in ex vivo human lung slices compared to approved antifibrotics nintedanib and pirfenidone.
• The REVERTIPF trial's preliminary blinded data showing over 50% of subjects with FVC values near or above baseline compares favorably to other recent IPF studies (e.g., Bexotegrast 320mg, Admilparant, Nerandomilast 2) where no placebo groups had mean FVC values near or above baseline.
• The REVERTIPF trial has broader enrollment criteria and a lower baseline percent predicted FVC (73.8%) compared to other trials like Sponsor Trial 1305-0013 (77.7%), BMS NCT04308681 (76.5%), and INTEGRIS-IPF NCT04396756 (78.1%), suggesting it is enrolling a more challenging patient population.
• In HCC, TTI-101 monotherapy's observed objective response rate (ORR) of 35% in HCC patients significantly exceeds the current expected ORR of less than 5% for second-line HCC therapies.
• Interim Phase 1b/2 data for REVERTLiver Cancer Cohort B (TTI-101 + Pembrolizumab) showed a 50% ORR, which compares favorably to Danvatirsen (STAT3 ASO) + Durvalumab in 2L HNSCC (23% ORR), noting Danvatirsen's limitations and eventual suspension.
• Interim Phase 1b/2 data for REVERTLiver Cancer Cohort C (TTI-101 + Atezo/Bev) showed an 8% ORR, which is lower than IMBrave150's 27% ORR for atezo/bev, but Tvardi notes their cohort has no HBV-associated HCC patients, which were associated with higher benefit in IMBrave150.

Stakeholder Impact

• Shareholders: The positive preliminary clinical data and upcoming key milestones could increase investor confidence and potentially lead to appreciation in share price.
• Patients (IPF & HCC): The development of TTI-101 and TTI-109 offers potential new, more effective treatment options for diseases with high unmet medical needs and poor prognoses.
• Employees: Continued positive clinical progress and pipeline expansion could lead to enhanced job security and growth opportunities within the company.
• Regulatory Authorities: The IND filing for TTI-109 and ongoing clinical trials demonstrate adherence to regulatory processes and progress towards potential drug approvals, which is favorable for regulatory oversight.

Next Steps

• Release of unblinded data from the Phase 2 REVERTIPF trial for Idiopathic Pulmonary Fibrosis in Q4 2025.
• Release of topline data from the Phase 1b/2 REVERTLiver Cancer trial for Hepatocellular Carcinoma in H1 2026.
• Commencement of clinical trials for TTI-109 in fibrosis and/or oncology, pending FDA feedback.

Key Dates

Recommendation

Keywords

Tvardi Therapeutics, TVRD, STAT3 Inhibitor, TTI-101, Idiopathic Pulmonary Fibrosis, IPF, Hepatocellular Carcinoma, HCC, Fibrosis, Oncology, Clinical Trials, Phase 2, Drug Development, Biotechnology, Rare Disease, Liver Cancer, TTI-109